 |
|
| CANCER DRUG DESIGN AND DISCOVERY
| |
| | |
|
|
To order this title, and for more information, click here
Edited By
Stephen Neidle, The School of Pharmacy, University of London, UK
Description
The ultimate source of information on the design of new anticancer agents, emphasising small molecules, this newest work covers recent
notable successes resulting from the human genome and cancer genomics projects. These advances have provided information on targets involved
in specific cancers that are leading to effective medicines for at least some of the common solid tumours. Unique sections explain the
basic underlying principles of cancer drug development and provide a practical introduction to modern methods of drug design. Appealing
to a broad audience, this is an excellent reference for translational researchers interested in cancer biology and medicine as well as
students in pharmacy, pharmacology, or medicinal and biological chemistry, and clinicians taking oncology options.
Audience
Translational researchers interested in cancer biology and medicine. Students in pharmacy, pharmacology, or medicinal and biological chemistry, as well as clinicians taking oncology options.
Contents
Section I. Basic Principles
1. Modern cancer drug discovery: Integrating targets, technologies and treatments
2. Preclinical pharmacology
and in vivo models
3. Clinical trial designs for more rapid proof-of-principle and approval
Section II. Methodology
4. Structural
biology and anticancer drug design
5. Natural product chemistry and cancer drug discovery
6. Pharmacokinetics & ADME optimization in
drug discovery
Section III. Drugs in the clinic and laboratory
7. Temozolomide: from cytotoxic to molecularly-targeted agent
8.
Camptothecins for drug design, cancer cell death and gene targeting
9. Targeting thymidylate synthase by antifolate drugs for the treatment
of cancer
Section IV. New Agents
10. Targeting inactive kinases: structure as a foundation for cancer drug discovery
11. Cell cycle
inhibitors in cancer: current status and future directions
12. Inhibition of DNA repair as a therapeutic target
13. Heat shock protein-90
inhibitors: targeting the cancer chaperone for combinatorial blockade of oncogenic pathways
14. Heat shock protein-90-directed therapeutics
and target validation
15. Inhibitors of tumour angiogenesis
16. The biology and oncology of RAF?ERK signalling P53 as a therapeutic target
Section V. The reality of cancer drugs in the clinic
17. Cancer drug resistance
18. Failure Modes in Anticancer Drug Discovery and Development
| Bibliographic details |
Hardbound, 496 pages, publication date: NOV-2007
ISBN-13: 978-0-12-369448-5
ISBN-10: 0-12-369448-5
Imprint: ACADEMIC PRESS
|
| Price and Ordering |
Price:
EUR 70.95
GBP 60
USD 94.95
|  |
Books and book related electronic products are priced in US dollars (USD), euro (EUR), and Great Britain Pounds (GBP). USD prices apply to the Americas and Asia Pacific. EUR prices apply in Europe and the Middle East. GBP prices apply to the UK and all other countries.
|
See also information about conditions of sale & ordering procedures, and links to our regional sales offices.
|
090/951
Last update: 5 Sep 2009
|
|
| |
| | |
|
|
| |
Home | Elsevier Sites | Privacy Policy | Terms and Conditions | Feedback | Site Map | A Reed Elsevier Company